



## **ST-Segment Elevation in Patients: An Update**

**Prashant Pawar, Rjaehs Bobade and Aniket Avhad**

Department Of Cardiology, Krishna Institute of Medical Sciences, Krishana Vishwa Vidyapeeth, Deemed to be University Karad

### **ABSTRACT**

*As we know through studies also that the, pandemic, showed a considerable increase in morbidity and mortality worldwide". Addition to this also showed that "CVS disorders in COVID-19 patients are at risk for acquiring include ACS, SIC, and myocarditis". So, concluded that "COVID-19 patient with STEMI had a higher risk of mortality and morbidity for all age & genders". Thus we have reviewed & evaluated STEMI.*

**Key words:** STEMI, COVID-19, pandemic, CVS, ACS.

Received 30.09.2023

Revised 25.10.2023

Accepted 31.11. 2023

### **INTRODUCTION**

Studies have also concluded that "when it comes to making a diagnosis of STEMI, a 12-lead electrocardiogram is the test that is considered to be the gold standard".[1] Studies have also concluded that "when a patient is experiencing acute chest pain and exhibits STE, the diagnosis of STEMI should be considered. It is feasible to combine multiple electrocardiogram recordings in addition to additional information from echocardiography and laboratory tests if there is uncertainty about the diagnosis". Alternative non-ischemic explanations may also be considered, especially in instances in which fewer characteristic symptoms are present, since only a small percentage of patients who arrive in the emergency room with chest pain and STE get a conclusive diagnosis of AMI. [2,3]

Studies have also concluded that "even though these patients would not directly benefit from the revascularization procedure, according to the guidelines, an urgent CAG may still be indicated to rule out obstructive CAD in the first instance, especially when there is uncertainty about the diagnosis. In other words, even though these patients would not directly benefit from the revascularization procedure, an urgent CAG may still be indicated". Studies have also concluded that "STEMI is a condition that occurs when TMI results in MI or necrosis".[1] Studies have also concluded that The new clinical definition of MI that came out in 2018 says that abnormal cardiac biomarkers must be used to prove myocardial ischemia injury. In January of this year, this was finally put into action. [2] It is a clinical syndrome that involves abnormalities in the EKG as well as chest pain and myocardial ischemia. This condition is known as acute coronary syndrome. Thus, we have reviewed & evaluated STEMI.

### **ETIOLOGY**

Studies have also concluded that "when one or more of the CA, which are responsible for supplying blood to the heart, get blocked, a person might suffer from a kind of heart attack known as an STEM-I".[3] Studies have also concluded that "there is often a sudden stop in the flow of blood because of plaque breaking apart, erosion, fissuring, or dissection of CA".[4] This creates an obstructive thrombus. The following diseases and disorders are considered to be among the most important risk factors for STEMI: dyslipidemia, DM, high BP, cigarette smoking, and a h/o CAD in the family. [3,4,5] On the other hand, studies have also concluded that the presence of a fixed occlusion in the CA is not required. Furthermore, studies have also concluded that Coronary asospasm(CA), CE, and spontaneous CAD (also known as SCAD) are three more probable causes of this condition. Type 3 MI is characterized by sudden cardiac death in patients who pass away prior to any troponin elevation. Procedures for coronary revascularization, such as PCI and CABG, are linked to types 4 and 5 of MI.

### **PATHOLOGY**

Studies have also concluded that in "order for there to be an elevation of ST-segment activity on a surface electrocardiogram due to an ATCE, there has to be a total occlusion of blood flow that lasts for an

extended period of time.”[5] Studies have also concluded that “ in STEMI , plaque rupture occurs with a sudden onset as well as the presence of TCFA was seen. All these changes the vascular endothelium, which sets off a chain reaction of platelets sticking together, activating, and building up, which leads to the start of thrombosis”.[6,7] This infarction may be seen as an abnormality in the electrical activity of the heart's surface. This takes place whenever there is a blockage in the CA. [8] In order to avoid damage to the myocardium, which starts occurring as soon as the blood flow is interrupted, immediate medical attention is absolutely necessary. Ischemia with a sudden onset is possible and may result in serious malfunction in the microvascular system.

Studies have also concluded that “patients who have COVID-19, shown to predispose to prothrombotic state, as well as their microvascular and macrovascular systems”.[9,10] Studies have also concluded that it has been shown that a “it is associated with a bad outcome in patients who are suffering from COVID-19 pneumonia”.[11,12,13] Studies have also concluded that in an Italian hospital, 40 patients died with COVID-19 ,35 percent of these patients had symptoms of MN. These microthrombi had a composition that was markedly different from that of thrombus aspirates taken from ECA. Those thrombus aspirates had a larger quantity of fibrin and terminal complement than these microthrombi. [14,15]

### **MANAGEMENT**

Studies have also concluded that following the “establishment of a diagnosis of AMI with STE, it is necessary to get intravenous access and to begin cardiac monitoring. However, recent investigations have shown that it is possible for oxygen therapy to have harmful repercussions in patients who are normoxic”.[16,17] Studies have also concluded that “.it is essential to rule out any diseases that can mimic an ACS, such as an acute aortic dissection or an acute pulmonary embolism. These conditions might be life-threatening. Both of these conditions have the ability to put a person's life in short order”.[18]

Studies have also found that people who are having an “AMI should start taking a beta-blocker, a high-intensity statin, aspirin, and a P2Y12 inhibitor right away, with a few exceptions”. Administering nitroglycerin may potentially relieve anginal pain. However, it is important to avoid this therapy in patients who have recently received PDE-inhibiting medication within the last twenty-four hours, as well as in cases of RVI.[19] Studies have concluded that patients experiencing persistent discomfort after nitroglycerin administration may get further pain relief from the administration of morphine. However, caution should be exercised while using morphine, as it may potentially have adverse effects on outcomes.[20] The selection of P2Y-inhibiting antiplatelet medication is contingent upon the patient's history of PCI or fibrinolytic therapy. Studies have also found that ticagrelor and prasugrel are better than clopidogrel for patients going through PCI because they had better results in recent clinical trials.[21,22] Initiate clopidogrel in patients undergoing fibrinolytic therapy.[23] Studies have also concluded that “extreme attention must be paid while considering the relative contraindications of P2Y12 inhibitors. Studies have also concluded that prasugrel is contraindicated for patients who have had a transient ischemic attack or stroke due to safety concerns”.[24]

### **COMPLICATION**

Studies have also concluded that the three mechanical repercussions of myocardial infarction that may be deadly are AMR, rupture of the IVS, and rupture of the free wall of the ventricles. Furthermore, studies have concluded that when ventricular free wall rupture occurs within 5 days, the overall mortality rate is around 80%, and it rises to 90% after 2 weeks.[25,26] Interventricular septum ruptures are documented nearly half as often as free-wall ruptures. They typically take place between three and five days after the initial injury and have an overall mortality rate of more than seventy percent.[27,28] In addition to that, studies concluded that when surgery is done as promptly as possible, the mortality rate for both diseases is reduced. When someone has a myocardial infarction, acute mitral regurgitation is most often caused by the ischemic papillary muscle shifting, the left ventricle getting bigger, or the papillary muscle of the chordae rupturing.[29] Patients with ST-elevation myocardial infarction have a correlation between the severity of mitral regurgitation and a 24% likelihood of survival after 30 days.[29]

### **LENGTH OF HOSPITAL STAY (LHS)**

Several studies have shown that patients diagnosed with STEMI during the pandemic had an overall longer LHS when compared to patients who are not suffering. [30,31]

### **IN HOSPITAL OUTCOME (IHO)**

There were several studies that showed that the main IHO, stroke, recurrent MI, or repeat revascularization was much higher in people with COVID-19 than in people without (36% vs. 5%, P.001). Studies have also concluded that this was mostly due to a considerably higher risk of IHO mortality in

patients with COVID-19 as compared with controls (33% vs. 4%, P.001).[31] Additionally, in Israel, people who were admitted to the hospital with STEMI during the pandemic were more likely to die or have a malignant arrhythmia than people who were not in the hospital during the pandemic (12% vs. 8.6%, P =.04). This was the case for those diagnosed with STEMI during the pandemic. During the pandemic, this was the situation for patients who had been admitted with STEMI.[32] Out-of-hospital and in-hospital patients with STEMI who had COVID-19 had a mortality rate that was significantly higher than 11.2% when compared with their counterparts who did not have COVID-19 and were propensity-matched for COVID-19 negativity. This was found out in major retrospective research that was completed not so long ago on patients with STEMI who also have COVID-19. In this research, studies have concluded that the IHO patients with STEMI who also had simultaneous COVID-19 were similar to the outcomes of in-hospital patients with STEMI who did not have COVID-19 from prior years. They discovered that those people who had contemporaneous COVID-19 had a mortality rate that was much higher than that of those who did not have COVID-19, with a rate of 76% as compared to 44%. This difference was statistically significant.[33]

### **MANAGEMENT IN COVID-19 ERA**

Studies have also concluded that multiple studies have shown that racial and ethnic minorities, such as African Americans, Asians, and Hispanics, had higher rates of mortality attributable to cardiovascular disease during the COVID-19 period as compared to whites. These findings were found in comparison to the white population.[34,35] Studies have also concluded that the likelihood ratio of AMI among ethnic minority groups was significantly higher when compared with whites, according to a retrospective examination of 73,746 patients admitted with AMI in the United Kingdom throughout the pandemic and pre-pandemic periods.[36] On the other hand, these patients were more likely to be younger than the usual patient, to be male, to have a lower body mass index, and to have a higher frequency of comorbidities. Additionally, they were more likely to have a lower body mass index. They were more likely to present with out-of-hospital cardiac arrest (7.6% vs. 6.2%, P =.04) and cardiogenic shock (3.5% vs. 2.4%, P =.001) as compared to whites. Studies have also found that the D2B time for the minority group increased by an absolute 30 minutes, resulting in a longer delay in the provision of reperfusion therapy than what white people experienced.[35] Studies have also concluded that ethnic minorities were significantly less likely to get discharged after receiving dual antiplatelet therapy as compared to whites (70% vs. 73%, P =.03). The risk of in-hospital and seven-day mortality was significantly higher for ethnic minority patients compared to whites.[35]

### **IMPACT OF PANDEMIC ON STEMI MANAGEMENT**

Studies have also concluded that the COVID-19 pandemic has had an effect on the delivery of health care in each and every one of its numerous dimensions throughout the entire world. There has also been a disruption in the care delivery systems for patients who are experiencing STEMI. These systems need the existence of a coordinated network of referral hospitals, emergency departments, and hospital labs that are capable of conducting PCI. During the early stages of the pandemic, a number of studies revealed that there was a reduction of up to 31% in the number of cardiac catheterization laboratory activations, as well as an estimated fall of 18% to 20% in the volume of primary PCI. Additionally, there was a decline of up to 20% in the number of primary PCI procedures performed. In addition, there was a reduction of as much as twenty percent in the total number of primary PCI procedures that were carried out.[36] A research investigation that Garcia and his colleagues carried out over the same time period as the pandemic revealed that there was a 20% increase in D2B timings when compared with the times that happened before the pandemic.[36] During the pandemic, it was said that there was an increase in time to reperfusion as a result of numerous distinct factors. This increase was attributed to the pandemic. These factors included the need to perform a COVID-19 screening in the emergency department (ED) before transferring a patient to the catheterization laboratory, the implementation of stringent infection control procedures, and the increased use of imaging to triage patients. [37]

Studies have also concluded that early on in the pandemic, it was observed that the time required to assess a patient in the emergency room was significantly longer than it had been in the years before the pandemic. This was a significant departure from the accepted norm.[31] Studies have also concluded that both the anxiety that hospital systems would become overloaded and the fear of being exposed to COVID-19 while in a hospital setting were significant factors.[38,39] Studies have further concluded that the process of providing care for these patients has been made more difficult due to a lack of appropriate medical experts, beds in intensive care units (ICUs), and other essential pieces of medical equipment, such as ventilators and mechanical circulatory support systems. The implementation of procedures that have received approval from cardiovascular societies as well as the expansion of access to COVID-19 testing

have both aided in the successful resolution of some of these challenges. Additionally, in order to alleviate the problem of a lack of beds in intensive care units (ICUs), it has been suggested that patients who are just at a low risk of having a STEMI should be triaged to other settings. This recommendation was made in order to help relieve the issue of a lack of beds in ICUs. This would make it possible to solve the issue of the lack of beds in intensive care units, which is now quite low. Risk ratings such as CADILLAC and Zwolle have been shown to be successful in the triage of patients who have low-risk STEMI in clinical settings that do not employ COVID-19. These risk ratings have been shown to be useful in clinical settings. These risk evaluations were potentially needed even more than they were before the pandemic.[40]

## CONCLUSION

We have come to conclusion that the COVID-19 pandemic constituted a significant risk to the status quo on a global scale and brought about substantial changes in the delivery of medical care. Studies have also concluded that COVID-19 presents a unique set of challenges with regard to the direct and indirect effects it has on patient care. The pathophysiology of the disease is only one of these challenges, as is the disturbance of resources in the health care system. As a result of the pandemic, important stress points within the health care system have been brought to light, prompting businesses to review their methods for resource allocation and management. Studies have also concluded that patients who have been diagnosed with ST-elevation myocardial infarction fall into a special category. This is because this particular patient group exhibits a distinct set of medical symptoms, necessitating the coordination of care by multidisciplinary teams. Studies have also concluded that it has brought to light the challenges that STEMI management must face in order to combat this pandemic. Multiple studies have shown that patients diagnosed with STEMI who also had COVID-19 had worse outcomes in the hospital compared to their counterparts who did not have COVID-19. These patients' outcomes were comparable to those of patients diagnosed with STEMI who did not have COVID-19. This was the case, despite the existence of a number of other factors. The racial and ethnic disparities in cardiovascular outcomes that were already recognized have become much more pronounced in the face of the pandemic. More research has to be done in order to have a better understanding of the effect that COVID-19 has on the long-term outcomes of patients with STEMI who survive their hospital stay and are discharged from the facility.

## REFERENCES

1. Antman, E., Bassand, J. P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., ... & Tendera, M. (2000). Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: the Joint European Society of Cardiology/American College of Cardiology Committee. *Journal of the American College of Cardiology*, 36(3), 959-969.
2. Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., ... & Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. (2018). Fourth universal definition of myocardial infarction (2018). *Circulation*, 138(20), e618-e651.
3. Wilson, P. W. (1994). Established risk factors and coronary artery disease: the Framingham Study. *American journal of hypertension*, 7(7\_Pt\_2), 7S-12S.
4. Canto, J. G., Kiefe, C. I., Rogers, W. J., Peterson, E. D., Frederick, P. D., French, W. J., ... & NRMI Investigators. (2011). Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. *Jama*, 306(19), 2120-2127.
5. Hartikainen, T. S., Sörensen, N. A., Haller, P. M., Goßling, A., Lehmacher, J., Zeller, T., ... & Neumann, J. T. (2020). Clinical application of the 4th Universal Definition of Myocardial Infarction. *European heart journal*, 41(23), 2209-2216.
6. Kolodgie, F. D., Burke, A. P., Farb, A., Gold, H. K., Yuan, J., Narula, J., ... & Virmani, R. (2001). The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. *Current opinion in cardiology*, 16(5), 285-292.
7. Scharf, R. E. (2018). Platelet signaling in primary haemostasis and arterial thrombus formation: Part 1. *Hämostaseologie*, 38(04), 203-210.
8. Reimer, K. A., & Jennings, R. B. (1979). The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. *Laboratory investigation; a journal of technical methods and pathology*, 40(6), 633-644.
9. Wichmann, D., Sperhake, J. P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., ... & Kluge, S. (2020). Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. *Annals of internal medicine*, 173(4), 268-277.
10. Levi, M., Thachil, J., Iba, T., & Levy, J. H. (2020). Coagulation abnormalities and thrombosis in patients with COVID-19. *The Lancet Haematology*, 7(6), e438-e440.
11. Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of thrombosis and haemostasis*, 18(4), 844-847.

12. Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., ... & Lip, G. Y. (2020). COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. *Journal of the American college of cardiology*, 75(23), 2950-2973.
13. Chan, N. C., & Weitz, J. I. (2020). COVID-19 coagulopathy, thrombosis, and bleeding. *Blood, The Journal of the American Society of Hematology*, 136(4), 381-383.
14. Pellegrini, D., Kawakami, R., Guagliumi, G., Sakamoto, A., Kawai, K., Gianatti, A., ... & Finn, A. V. (2021). Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study. *Circulation*, 143(10), 1031-1042.
15. Fardman, A., Zahger, D., Orvin, K., Oren, D., Kofman, N., Mohsen, J., ... & Matetzky, S. (2021). Acute myocardial infarction in the Covid-19 era: Incidence, clinical characteristics and in-hospital outcomes—A multicenter registry. *PLoS One*, 16(6), e0253524.
16. Stub, D., Smith, K., Bernard, S., Nehme, Z., Stephenson, M., Bray, J. E., ... & Kaye, D. M. (2015). Air versus oxygen in ST-segment-elevation myocardial infarction. *Circulation*, 131(24), 2143-2150.
17. Hofmann, R., James, S. K., Jernberg, T., Lindahl, B., Erlinge, D., Witt, N., ... & Svensson, L. (2017). Oxygen therapy in suspected acute myocardial infarction. *New England Journal of Medicine*, 377(13), 1240-1249.
18. O'gara, P. T., Kushner, F. G., Ascheim, D. D., Casey Jr, D. E., Chung, M. K., De Lemos, J. A., ... & Zhao, D. X. (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*, 127(4), 529-555.
19. Meine, T. J., Roe, M. T., Chen, A. Y., Patel, M. R., Washam, J. B., Ohman, E. M., ... & Crusade Investigators. (2005). Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. *American heart journal*, 149(6), 1043-1049.
20. Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., ... & Antman, E. M. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. *New England Journal of Medicine*, 357(20), 2001-2015.
21. Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., ... & Harrington, R. A. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *New England Journal of Medicine*, 361(11), 1045-1057.
22. Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., ... & Braunwald, E. (2005). Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *New England Journal of Medicine*, 352(12), 1179-1189.
23. Stub, D., Smith, K., Bernard, S., Nehme, Z., Stephenson, M., Bray, J. E., ... & Kaye, D. M. (2015). Air versus oxygen in ST-segment-elevation myocardial infarction. *Circulation*, 131(24), 2143-2150.
24. Braun, M., & Kassop, D. (2020). Acute Coronary Syndrome: Management. *FP essentials*, 490, 20-28.
25. Batts, K. P., Ackermann, D. M., & Edwards, W. D. (1990). Postinfarction rupture of the left ventricular free wall: clinicopathologic correlates in 100 consecutive autopsy cases. *Human pathology*, 21(5), 530-535.
26. Yip, H. K., Wu, C. J., Chang, H. W., Wang, C. P., Cheng, C. I., Chua, S., & Chen, M. C. (2003). Cardiac rupture complicating acute myocardial infarction in the direct percutaneous coronary intervention reperfusion era. *Chest*, 124(2), 565-571.
27. Figueras, J., Alcalde, O., Barrabés, J. A., Serra, V., Alguersuari, J., Cortadellas, J., & Lidón, R. M. (2008). Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. *Circulation*, 118(25), 2783-2789.
28. Crenshaw, B. S., Granger, C. B., Birnbaum, Y., Pieper, K. S., Morris, D. C., Kleiman, N. S., ... & Topol, E. J. (2000). Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. *Circulation*, 101(1), 27-32.
29. Tchong, J. E., Jackman Jr, J. D., Nelson, C. L., Gardner, L. H., Smith, L. R., Rankin, J. S., ... & Stack, R. S. (1992). Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. *Annals of internal medicine*, 117(1), 18-24.
30. Garcia, S., Dehghani, P., Grines, C., Davidson, L., Nayak, K. R., Saw, J., ... & Society For Cardiac Angiography and Interventions, the Canadian Association of Interventional Cardiology, and the American College of Cardiology Interventional Council. (2021). Initial findings from the North American COVID-19 myocardial infarction registry. *Journal of the American College of Cardiology*, 77(16), 1994-2003.
31. Chew, N. W., Ow, Z. G. W., Teo, V. X. Y., Heng, R. R. Y., Ng, C. H., Lee, C. H., ... & Loh, P. H. (2021). The global effect of the COVID-19 pandemic on STEMI care: a systematic review and meta-analysis. *Canadian Journal of Cardiology*, 37(9), 1450-1459.
32. Fardman, A., Zahger, D., Orvin, K., Oren, D., Kofman, N., Mohsen, J., ... & Matetzky, S. (2021). Acute myocardial infarction in the Covid-19 era: Incidence, clinical characteristics and in-hospital outcomes—A multicenter registry. *PLoS One*, 16(6), e0253524.
33. Saad, M., Kennedy, K. F., Imran, H., Louis, D. W., Shippey, E., Poppas, A., ... & Aronow, H. D. (2021). Association between COVID-19 diagnosis and in-hospital mortality in patients hospitalized with ST-segment elevation myocardial infarction. *Jama*, 326(19), 1940-1952.
34. Wadhera, R. K., Figueroa, J. F., Rodriguez, F., Liu, M., Tian, W., Kazi, D. S., ... & Joynt Maddox, K. E. (2021). Racial and ethnic disparities in heart and cerebrovascular disease deaths during the COVID-19 pandemic in the United States. *Circulation*, 143(24), 2346-2354.
35. Rashid, M., Timmis, A., Kinnaird, T., Curzen, N., Zaman, A., Shoaib, A., ... & Mamas, M. (2021). Racial differences in management and outcomes of acute myocardial infarction during COVID-19 pandemic. *Heart*, 107(9), 734-740.

36. Garcia, S., Stanberry, L., Schmidt, C., Sharkey, S., Megaly, M., Albaghdadi, M. S., ... & Henry, T. D. (2021). Impact of COVID-19 pandemic on STEMI care: an expanded analysis from the United States. *Catheterization and cardiovascular interventions*, 98(2), 217-222.
37. Bangalore, S., Sharma, A., Slotwiner, A., Yatskar, L., Harari, R., Shah, B., ... & Hochman, J. S. (2020). ST-segment elevation in patients with Covid-19—a case series. *New England Journal of Medicine*, 382(25), 2478-2480.
38. Roffi, M., Guagliumi, G., & Ibanez, B. (2020). The obstacle course of reperfusion for ST-segment-elevation myocardial infarction in the COVID-19 pandemic. *Circulation*, 141(24), 1951-1953.
39. Piccolo, R., Bruzzese, D., Mauro, C., Aloia, A., Baldi, C., Boccalatte, M., ... & Esposito, G. (2020). Population trends in rates of percutaneous coronary revascularization for acute coronary syndromes associated with the COVID-19 outbreak. *Circulation*, 141(24), 2035-2037.
40. Lopez, J. J., Ebinger, J. E., Allen, S., Yildiz, M., & Henry, T. D. (2021). Adapting STEMI care for the COVID-19 pandemic: The case for low-risk STEMI triage and early discharge. *Catheterization and Cardiovascular Interventions*, 97(5), 847-849.

#### **CITATION OF THIS ARTICLE**

Prashant Pawar, Rjaehs Bobade and Aniket Avhad. St-Segment Elevation In Patients: An Update. *Bull. Env. Pharmacol. Life Sci., Spl Issue [2]: 2023: 507-512.*